AmbioPharm, a peptide manufacturer headquartered in North Augusta, announced on June 16, 2026, that it will invest $118.96 million to expand its operations in Aiken County. The company plans to construct a modular manufacturing building at its existing campus located at 1024 Dittman Court in North Augusta. According to the release, the project will create 202 new jobs and bring production systems online by the end of 2027.
What it means
The expansion adds commercial-scale Good Manufacturing Practice (GMP) synthesis capacity to AmbioPharm’s existing facility. The new building will support solid-phase peptide synthesis, liquid-phase peptide synthesis, and hybrid approaches for active pharmaceutical ingredients and new chemical entities. Production systems within the facility will be semi-automated and utilize advanced solvent delivery infrastructure.
An AmbioPharm representative stated that the expansion enhances the company’s ability to support client-partners with scalable, high-quality production as global demand for peptide therapeutics accelerates. Aiken County Council Chairman Gary Bunker said the investment is a vote of confidence in the community’s workforce and business climate.
Key facts
- $118.96 million: Total investment amount for the expansion, according to the company.
- 202 jobs: Number of new positions created by the project, according to the company.
- North Augusta, S.C.: Location of the existing campus at 1024 Dittman Court where the modular building will be constructed.
- End of 2027: Expected date for operations to come online.
- GMP synthesis: The facility will offer commercial-scale synthesis including solid-phase, liquid-phase, and hybrid methods.
Source: AmbioPharm news release